Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer

Clinical Biochemistry

Volumn 42, Issue 13-14, 2009, Pages 1420-1426

  Taha, Fatma M ^a   Zeeneldin, Ahmed A ^b   Helal, Amani M ^b   Gaber, Ayman A ^b   Sallam, Yasser A ^b   Ramadan, Hanan ^b   Moneer, Manar M ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Anthracycline; Egypt; First line chemotherapy; Metastases; Triple receptor negative breast cancer; Vascular endothelial growth factor

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; VASCULOTROPIN A;

ADULT; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; EGYPT; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLEURA METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SKIN METASTASIS; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER; VISCERAL METASTASIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; DISEASE PROGRESSION; DOXORUBICIN; EGYPT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69249212216     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.06.022     Document Type: Article

References (54)

1. Cleator S., Heller W., and Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 8 3 (2007 Mar) 235-244
2. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10 Suppl 3 (2005) 20-29
3. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., and Ellis I.O. Prognostic markers in triple-negative breast cancer. Cancer 109 1 (2007 Jan 1) 25-32
4. Tischkowitz M., Brunet J.S., Begin L.R., et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7 (2007) 134
5. Bernard-Marty C., Cardoso F., and Piccart M.J. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 9 6 (2004) 617-632
6. Guarneri V., Broglio K., Kau S.W., et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 24 7 (2006 Mar 1) 1037-1044
7. Urruticoechea A., Smith I.E., and Dowsett M. Proliferation marker Ki-67 in early breast cancer. J. Clin. Oncol. 23 28 (2005 Oct 1) 7212-7220
8. Sledge G.W., Neuberg D., Bernardo P., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 21 4 (2003 Feb 15) 588-592
9. Cresta S., Grasselli G., Mansutti M., et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer. Ann. Oncol. 15 3 (2004 Mar) 433-439
10. Conte P.F., Guarneri V., Bruzzi P., et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101 4 (2004 Aug 15) 704-712
11. Alba E., Martin M., Ramos M., et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J. Clin. Oncol. 22 13 (2004 Jul 1) 2587-2593
12. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J. Clin. Oncol. 16 10 (1998 Oct) 3439-3460
13. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5 Suppl 1 (2000) 37-44
14. Linderholm B., Grankvist K., Wilking N., Johansson M., Tavelin B., and Henriksson R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol. 18 7 (2000 Apr) 1423-1431
15. Berns E.M., Klijn J.G., Look M.P., et al. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin. Cancer Res. 9 4 (2003 Apr) 1253-1258
16. Foekens J.A., Peters H.A., Grebenchtchikov N., et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 61 14 (2001 Jul 15) 5407-5414
17. Toi M., Matsumoto T., and Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2 11 (2001 Nov) 667-673
18. Konecny G.E., Meng Y.G., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin. Cancer Res. 10 5 (2004 Mar 1) 1706-1716
19. Heer K., Kumar H., Read J.R., Fox J.N., Monson J.R., and Kerin M.J. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin. Cancer Res. 7 11 (2001 Nov) 3491-3494
20. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000 Feb 2) 205-216
21. Verheul H.M., and Pinedo H.M. The importance of platelet counts and their contents in cancer. Clin. Cancer Res. 7 (2003 Aug 15) 3219-3221
22. Wynendaele W., Derua R., Hoylaerts M.F., et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?. Ann. Oncol. 10 (1999) 965-971
23. Lee J.K., Hong Y.J., Han C.J., Hwang D.Y., and Hong S.I. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int. J. Oncol. 17 (2000) 149-152
24. Ferrero S., Nicoletti A., and Ragni N. Letter to the editor: measurement of serum vascular endothelial growth factor in breast cancer patients. Intern. Med. J. 35 (2005) 310-314
25. Bauer K.R., Brown M., Cress R.D., Parise C.A., and Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109 9 (2007 May 1) 1721-1728
26. Haffty B.G., Yang Q., Reiss M., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24 36 (2006 Dec 20) 5652-5657
27. Bidard F.C., Conforti R., Boulet T., Michiels S., Delaloge S., and Andre F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann. Oncol. 18 7 (2007 Jul) 1285-1286
28. Aksoy S., Dizdar O., Harputluoglu H., and Altundag K. Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. Ann. Oncol. 18 11 (2007 Nov) 1904-1906
29. Kreike B., van Kouwenhove M., Horlings H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res. 9 5 (2007 Oct 2) R65
30. Rodriguez-Pinilla S.M., Sarrio D., Honrado E., et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin. Cancer Res. 12 5 (2006 Mar 1) 1533-1539
31. Osborne C.R., Kannan L., Ashfaq R., Ariyibi J., Frawley W.H., and Tripathy D. Clinical and pathological characterization of basal-like breast cancer. Poster presentation: 2098 San Antonio. Breast Cancer Symp. (2007) 2007
32. Bontenbal M., Creemers G.J., Braun H.J., et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J. Clin. Oncol. 23 28 (2005 Oct 1) 7081-7088
33. Mackey J.R., Tonkin K.S., Koski S.L., et al. Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer. Clin. Breast Cancer 5 4 (2004 Oct) 287-292
34. Jassem J., Pienkowski T., Pluzanska A., et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J. Clin. Oncol. 19 6 (2001 Mar 15) 1707-1715
35. Gennari A., Sormani M.P., Pronzato P., et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J. Natl. Cancer Inst. 100 1 (2008 Jan 2) 14-20
36. Keam B., Im S.A., Kim H.J., et al. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer 7 (2007 Nov 1)
37. Uhm J.E., Park Y.H., Yi S.Y., et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int. J. Cancer 124 6 (2009 Mar 15) 1457-1462
38. Sirohi B., Arnedos M., Popat S., et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann. Oncol. 19 11 (2008 Nov) 1847-1852
39. Yamamoto Y., Toi M., Kondo S., et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin. Cancer Res. 2 5 (1996 May) 821-826
40. Adams J., Cander P.J., Downey S., et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 60 11 (2000 Jun 1) 2898-2905
41. Kraft A., Weindel K., Ochs A., et al. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 85 1 (1999 Jan 1) 178-187
42. Salven P., Perhoniemi V., Tykka H., Maenpaa H., and Joensuu H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res. Treat. 53 2 (1999 Jan) 161-166
43. Salven P., Manpaa H., Orpana A., Alitalo K., and Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin. Cancer Res. 3 5 (1997 May) 647-651
44. Linderholm B., Lindh B., Tavelin B., Grankvist K., and Henriksson R. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int. J. Cancer 89 1 (2000 Jan 20) 51-62
45. Dirix L.Y., Vermeulen P.B., Pawinski A., et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer 76 2 (1997) 238-243
46. Manders P., Beex L.V., Tjan-Heijnen V.C., Span P.N., and Sweep C.G. Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 98 10 (2003 Nov 15) 2125-2132
47. Linderholm B.K., Lindahl T., Holmberg L., et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61 5 (2001 Mar 1) 2256-2260
48. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357 26 (2007 Dec 27) 2666-2676
49. Burstein H.J., Elias A.D., Rugo H.S., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26 11 (2008 Apr 10) 1810-1816
50. Mills P.J., Parker B., Jones V., et al. The effects of standard anthracycline-based chemotherapy on soluble ICAM-1 and vascular endothelial growth factor levels in breast cancer. Clin. Cancer Res. 10 15 (2004 Aug 1) 4998-5003
51. Verheul H.M., Hoekman K., Luykx-de Bakker S., et al. Platelet: transporter of vascular endothelial growth factor. Clin. Cancer Res. 3 12 Pt 1 (1997 Dec) 2187-2190
52. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 6 (2004 Jun) 423-436
53. Colleoni M., Rocca A., Sandri M.T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13 1 (2002 Jan) 73-80
54. Sirohi B., and Smith K. Bevacizumab in the treatment of breast cancer. Expert Rev. Anticancer Ther. 8 10 (2008 Oct) 1559-1568